NCT04605211View on ClinicalTrials.gov

A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors

NACompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

September 18, 2020

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Myeloproliferative NeoplasmChronic Phase Chronic Myelogenous LeukemiaChronic Myeloid Leukemia
Interventions
BEHAVIORAL

Online Mindfulness Meditation

Complete online audio-based mindfulness meditation exercises

OTHER

Internet-Based Webinars

Attend webinars

Trial Locations (1)

94143

University of California San Francisco, San Francisco

All Listed Sponsors
collaborator

American Society of Hematology

OTHER

lead

University of California, San Francisco

OTHER

NCT04605211 - A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors | Biotech Hunter | Biotech Hunter